New migraine pill lasmiditan shows promise in Real-World study
NCT ID NCT05903040
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how well and how safely lasmiditan works for treating migraine attacks. One hundred adults with migraine took lasmiditan tablets (50, 100, or 200 mg) when they had an attack. Researchers measured how many people were pain-free after 2 hours and tracked any side effects. The goal was to see if lasmiditan is a good option for quick migraine relief in everyday use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lasmiditan (oral tablet, 50-100-200 mg)
- What this could lead to
- If successful, this could confirm lasmiditan as a well-tolerated option for stopping migraine pain quickly.
- What could go wrong
- This is a small, completed observational study (100 people) without a placebo group, so results may not prove effectiveness compared to no treatment or other drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IRCCS National Neurological Institute "C. Mondino" Foundation
Pavia, 27100, Italy
-
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
Florence, 50134, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a No-Fridge migraine shot replace botox?
- Mind over migraine: brain network may explain why some expect side effects
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?
- Could a common cholesterol drug stop chronic migraine?
- Experimental migraine drug JS010 takes first step in human safety trial
- Scientists probe shared pain pathways in endometriosis and migraine